GIZ943 / Novartis - LARVOL DELTA

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2030 ➔ Jul 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Aug 2030 ➔ Jul 2025; Study termination based on sponsor decision due to lack of tolerability observed with [177Lu]Lu-EVS459

Trial completion date • Trial primary completion date • Trial termination • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers (clinicaltrials.gov) - P1 | N=4 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=96 ➔ 4

Enrollment change • Enrollment closed • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Discovery of [177Lu]Lu-EVS459, a novel low-molecular weight radioligand therapy for the treatment of folate receptor positive cancers (EANM 2024) - "Due to its highly restricted expression in normal tissues, FRα is an attractive target for anti-cancer therapies, as demonstrated with the antibody-drug conjugate mirvetuximab soravtansine, recently approved by the FDA for the treatment of FRα-positive ovarian cancer. We disclose the discovery and identity of lutetium-177 or gallium-68 radiolabeled EVS459, a novel low-molecular weight FR-targeting radiopharmaceutical. Preclinical evaluation of [177Lu]Lu-EVS459 supports its clinical development as a radioligand therapy targeting FR-positive tumors in patients. A phase 1 study is ongoing to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-EVS459, as well as the safety and PET imaging properties of [68Ga]Ga-EVS459, see reference."

Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor